Abstract
Background
Uganda’s efforts to end the HIV epidemic by 2030 are threatened by the increasing number of PLHIV with low-level viraemia (LLV). We conducted a study to determine the prevalence of LLV and the association between LLV and subsequent viral non-suppression from 2016 to 2020 among PLHIV on ART in Uganda.
Method
This was a retrospective cohort study, using the national viral load (VL) program data from 2016 to 2020. LLV was defined as a VL result of at least 50 copies/ml, but less than 1,000 copies/ml. Multivariable logistic regression was used to determine the factors associated with LLV, and cox proportional hazards regression model was used to determine the association between LLV and viral non-suppression.
Results
A cohort of 17,783 PLHIV, of which 1,466 PLHIV (8.2%) had LLV and 16,317 (91.8%) had a non-detectable VL was retrospectively followed from 2016 to 2020. There were increasing numbers of PLHIV with LLV from 2.0% in 2016 to 8.6% in 2020; and LLV was associated with male sex, second line ART regimen and being of lower age. 32.5% of the PLHIV with LLV (476 out of 1,466 PLHIV) became non-suppressed, as compared to 7.7% of the PLHIV (1,254 out of 16,317 PLHIV) with a non-detectable viral load who became non-suppressed during the follow-up period. PLHIV with LLV had 4.1 times the hazard rate of developing viral non-suppression, as compared to PLHIV with a non-detectable VL (adjusted hazard ratio was 4.1, 95% CI: 3.7 to 4.7, p < 0.001).
Conclusion
Our study indicated that PLHIV with LLV increased from 2.0% in 2016 to 8.6% in 2020, and PLHIV with LLV had 4.1 times the hazard rate of developing viral non-suppression, as compared to PLHIV with a non-detectable VL. Hence the need to review the VL testing algorithm and also manage LLV in Uganda.
Funder
NIH Fogarty International Center
NINDS
NIMH
Publisher
Public Library of Science (PLoS)
Reference37 articles.
1. Antiretroviral Drug Discovery and Development | NIH: National Institute of Allergy and Infectious Diseases [Internet]. [cited 2021 Nov 6]. Available from: https://www.niaid.nih.gov/diseases-conditions/antiretroviral-drug-development
2. Twenty Years Of Antiretroviral Therapy For People Living With HIV: Global Costs, Health Achievements, Economic Benefits.;SS Forsythe;Health Affairs.,2019
3. Global HIV & AIDS statistics—Fact sheet [Internet]. [cited 2021 Jun 21]. Available from: https://www.unaids.org/en/resources/fact-sheet
4. Uganda [Internet]. [cited 2021 Jun 21]. Available from: https://www.unaids.org/en/regionscountries/countries/uganda
5. Uganda Viral Load Dashboard [Internet]. [cited 2021 Jun 22]. Available from: https://vldash.cphluganda.org/